TeamDrive
RUS
Maxim Chernin

Maxim Chernin

Partner

Телефоны:

+7 495 545-39-12

Send message

Maxim has joined to the "Team Drive" in October 2017.

Before that, he headed the Client’s Welfare Department of Sberbank as a Managing director. He was a board member of subsidiaries and played a key part in developing insurance, pension and investment activity of this biggest Russian bank. In 2010 as a CEO Maxim organized from scratch “Sberbank life insurance” project. Today it is recognized market leader in its field. Maxim’s professional record includes 10 years experience in insurer company Allianz (former ROSNO). He started as a specialist of marketing research department and in few years he became a member of the Management Board with a wide range of responsibilities. Companies and departments had been growing strongly under his guidance. His management was cost-effective, profitable for shareholders and provided high-quality services for the clients.

Now Maxim is a member of the Government Expert Council of the Russian Federation and of the Public Council under the Ministry of Health of the Russian Federation.

Since 2010 Maxim leads the committee of life insurance in the All-Russian Insurance Association (ARIA). He is also a member of the Board of the All-Russian Insurance Association and of the Association of Life Insurers. In addition, Maxim is a Board member of PJSC Rosgosstrakh insurance company.

In 2017, Maxim was awarded by the National Financial Award “Reputation” in the nomination “For Personal Merits in the Development of Insurance in Russia”. In 2016 he was included into the “Top 250 of the Russian principals” rating according to the estimation of “Kommersant” magazine. In 2014, Maxim was awarded the ARIA honorary medal "For Merits in the Development of Insurance in Russia". In 2011, the “Finance” magazine included Maxim in the annual list of the most successful young businessperson in Russia.

Maxim graduated with honours from the National Research University “Higher School of Economics” majoring in “Strategic Management”.

Media Center

  • 19 September 2018

    Russia approves new state strategy for pharmaceutical industry

    A new state strategy for the development of the domestic pharmaceutical industry, known as "Strategy for the development of the pharmaceutical industry of Russia until 2030," has been recently approved by the Russian Ministry of Industry and Trade, with the aim to bring the Russian pharmaceutical production to a new level.

  • 18 September 2018

    The Ministry of Health of the Russian Federation improves patent protection law

    The Ministry of Health of Russia has published a notification on the development of amendments to Federal Law No. 61 of 12.04.2010 “On circulation of medicinal products”, designed to synchronize it with regulatory acts of the Eurasian Economic Union. The procedure for registration of the medicinal product will be corrected.

  • 17 September 2018

    GlobalData published new report on the Top 25 pharma companies

    The performance highlights of the Top 25 publicly traded global pharmaceutical companies by Market Cap (Mcap) for the quarter ended June 30, 2018 (Q2), compared to the quarter ended March 31, 2018 (Q1), have been analyzed in the latest research from GlobalData, a leading data and analytics company.

  • 14 September 2018

    US scientists conduct clinical trial of influenza vaccine with imiquimod

    A Phase 1 clinical trial examining whether a topical cream can enhance the immune response conferred by a “pre-pandemic” influenza vaccine is underway at Baylor College of Medicine in Houston (USA). Investigators are evaluating whether imiquimod cream, which is commonly used to treat genital warts and certain skin cancers, can boost the body’s immune response to an H5N1 influenza vaccine. The trial is enrolling 50 healthy adults ages 18-50 years. 

Read more